L
Lorna Hazell
Researcher at University of Portsmouth
Publications - 15
Citations - 2536
Lorna Hazell is an academic researcher from University of Portsmouth. The author has contributed to research in topics: Pharmacovigilance & Yellow Card Scheme. The author has an hindex of 12, co-authored 15 publications receiving 2126 citations.
Papers
More filters
Journal ArticleDOI
Under-reporting of adverse drug reactions : a systematic review.
Lorna Hazell,Saad A. W. Shakir +1 more
TL;DR: Evidence of significant and widespread under-reporting of ADRs to spontaneous reporting systems including serious or severe ADRs is provided.
Journal ArticleDOI
Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank
Andrea V. Margulis,Manel Pladevall,Nuria Riera-Guardia,Cristina Varas-Lorenzo,Lorna Hazell,Nancy D. Berkman,Meera Viswanathan,Susana Perez-Gutthann +7 more
TL;DR: The RTI-IB facilitates a more complete quality assessment than the NOS but is more burdensome; the observed agreement and AC1 statistic in this study were higher than those reported by the RTI’s developers.
Journal ArticleDOI
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Anthony J Avery,Claire Anderson,Christine Bond,Heather Fortnum,Alison Gifford,Philip C Hannaford,Lorna Hazell,Janet Krska,Amanda J Lee,David J. McLernon,Elizabeth Murphy,Saad A. W. Shakir,Margaret C Watson,Margaret C Watson +13 more
TL;DR: Patient reporting of suspected ADRs has the potential to add value to pharmacovigilance by reporting types of drugs and reactions different from those reported by HCPs; generating new potential signals; and describing suspectedADRs in enough detail to provide useful information on likely causality and impact on patients' lives.
Journal ArticleDOI
Analysis and reporting of adverse events in randomised controlled trials: a review.
TL;DR: It is highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused.
Journal ArticleDOI
Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
David J. McLernon,Christine Bond,Philip C Hannaford,Margaret C Watson,Amanda J Lee,Lorna Hazell,Anthony J Avery +6 more
TL;DR: In the UK, spontaneous reporting of suspected adverse drug reactions (ADRs) by healthcare professionals has been in operation since 1964 through the Yellow Card Scheme (YCS), from 2005, patients themselves have been able to submit Yellow Card reports.